Ever since their discovery multidrug resistance (MDR) transporters have provided a plethora of fascinating and challenging topics for fundamental and applied research. Recognized first as a cause of resistance of tumor cells to anticancer agents (reviewed in reference 5), they were later discovered in all living organisms, from bacteria to humans. In bacteria the expression of MDR transporters can raise antibiotic resistance by several orders of magnitude, rendering some antibiotics clinically useless, especially against gram-negative pathogens (reviewed in reference 30). The structural diversity of substrates for some MDR pumps is striking: a single efflux system may accommodate positively or negatively charged compounds, as well as compounds that are neutral or zwitterionic (reviewed in reference 20) . Establishing the basis for multidrug recognition and transport, which provides a single protein with both broad specificity and high selectivity, is a fundamentally intriguing challenge. Aside from being intellectually rewarding, unraveling the mechanistic details will greatly facilitate the fight to combat antibiotic resistance. The results of the study by Aires and Nikaido published in this issue of the Journal of Bacteriology (1a) , demonstrating that MDR transporter AcrD could capture its substrates directly from the periplasm and extrude them into the external medium, bring us one step closer to elucidation of this fascinating biochemical process.
The AcrD transporter from Escherichia coli (32) is a typical member of the resistance-nodulation-division (RND) family (37), which includes the major agents of intrinsic and acquired antibiotic resistance in gram-negative bacteria-pathogens which pose a great clinical challenge owing to their decreasing susceptibility to the majority of current antibacterial agents. In fact, out of all approved antibiotics (some 160 antibiotics), representatives of only three classes (fluoroquinolones, betalactams, and aminoglycosides) have any clinical utility for the treatment of Pseudomonas aeruginosa infections. Even these antibiotics are under threat from multiple mechanisms of acquired resistance, with MDR efflux pumps playing a prominent role (reviewed in reference 31). The problem becomes even more serious because MDR efflux pumps can act on newer compounds in development that have been identified and optimized using all the powerful techniques of modern drug discovery such as comparative genomics, structure-guided drug design, and combinatorial chemistry.
It would be unfair to attribute the extent of intrinsic and acquired resistance in gram-negative bacteria (which may reach several orders of magnitude) solely to the activity of MDR pumps; such pumps also exist in gram-positive bacteria. What is different is the so-called transenvelope efflux, whereby a toxic compound is extruded directly into the external medium, from which entry is slowed by the outer membrane, which retards both hydrophilic and hydrophobic compounds (reviewed in references 29 and 44). Transenvelope multidrug efflux is performed by tripartite protein complexes comprised of an inner membrane transporter, an outer membrane channel (OMP), and a membrane fusion protein (MFP) located in the periplasm. While tripartite systems may contain MDR transporters from different families (33) , it is the RND-containing ones that have been studied the most.
Progress in elucidating the structural biology of these tripartite pumps has been remarkable, yielding high-resolution three-dimensional (3D) structures of all three individual components. The structure of the E. coli OMP TolC was solved in 2000 (18) . Quite recently, the structure of the P. aeruginosa OMP OprM became available (2) . The structure of the E. coli RND protein AcrB was published in 2002 (26), followed by the structure of the same protein in combination with several ligands in 2003 (40) , and the structure of the last player, the MFP component, MexA from P. aeruginosa (3, 17) was reported in 2004.
X-ray crystallography provides a strong structural basis to define the process of transenvelope efflux. Both AcrB and TolC are homotrimers and contain large periplasmic domains. There appears to be a perfect fit between the funnel-like opening of the headpiece of AcrB and the proximal end of the tunnel-like TolC. Thus the deep "crater" at the tip of the periplasmic segment of AcrB may serve as a portal connecting to the TolC subunit. The latter likely serves as an "exhaust pipe," conducting the substrates expelled by the pump through the outer membrane and into the extracellular space. Indeed, the sum of the periplasmic lengths of AcrB and TolC (170 Å ) is large enough to cross the entire periplasmic space. Recent studies have demonstrated that AcrB and TolC can be crosslinked in vivo, experimentally confirming the close proximity of their periplasmic domains (36) . As for the MFP, based on its interactions with the other two components of the system (25, 42) , it was concluded that this protein is required for stable association of the inner and outer membrane components of the pump. The 3D structure of the MFP MexA is compatible with this interpretation (3, 17 ). An unexpected finding by Aires and Nikaido suggests, however, an additional and perhaps more active role for the MFP (see below).
The 3D architecture of the AcrB trimer is extremely interesting (reviewed in references 9 and 28). It revealed three large vestibules, formed by neighboring protomers, wide open to the periplasm. These vestibules lead to a central cavity inside the pump, inviting the speculation that substrates gain access to the pump from the periplasmic space and that this spacious cavity serves as a binding site for multiple substrates. And indeed, in later cocrystallization studies several structurally unrelated substrates of AcrB were bound in the central cavity (39) .
The structural studies indicate that RND transporters could capture their substrates directly from the periplasm or from the outer leaflet of the cytoplasmic membrane. This conclusion is in good agreement with results from several laboratories that indicate that residues in two large periplasmic loops of RND transporters determine their substrate specificity (8, 11, 12, 22, 24, 27, 35) .
Missing from this logical picture is biochemical evidence of periplasmic capture of substrates. Such evidence is now provided by the elegant study of Aires and Nikaido (1a) . To assess the location of substrate capture by the RND transporter, they used the well-defined system of reconstituted proteosomes with an artificially imposed proton gradient (in their case, inside acidic, defining the intravesicular space as the "periplasm"). Such a system should allow the determination of activity of a transporter depending on whether a substrate is added to the external medium (the "cytoplasm") or is exclusively present in the intravesicular space (the periplasm). However, the construct can serve as a model for an efflux system only if the substrate cannot spontaneously cross the membrane. Highly charged aminoglycoside antibiotics satisfy this criterion, and this dictated the choice of the RND transporter AcrD from E. coli, which is known to extrude aminoglycosides as part of the AcrA-AcrD-TolC tripartite MDR. In this system cytoplasmic capture should result in (radiolabeled) substrate movement across the membrane and accumulation in the intravesicular space, where it can be measured directly. Conversely, periplasmic capture by AcrD would not move the substrate across the membrane, so an indirect way to detect the binding event was needed. The authors reasoned that since the activity of RND transporters is driven by proton gradients (13, 41) , substrate capture and release should be accompanied by the transport of proton across the membrane, resulting in dissipation of the artificially imposed gradient. Using this proton transport assay, Aires and Nikaido provided the first evidence for the periplasmic capture of aminoglycosides by AcrD. Interestingly, their experiments also demonstrated that some, but not all, aminoglycosides could be captured from the cytoplasmic side of the membrane. What was not anticipated and came as a complete surprise was the absolute essentiality of AcrA for both periplasmic and cytoplasmic capturing: proton transport was recorded only when AcrA was present within proteoliposomes.
Thus, it appears that AcrA plays some important (but unknown) role in RND-mediated transport in addition to facilitating the assembly of the tripartite complex. Does an RND transporter need to be "activated" by the MFP protein in order to capture its substrates? Perhaps cocrystallization of the RND and MFP components can provide an accurate picture of potential substrate binding pockets.
Interestingly, the presence of AcrA makes AcrB proteoliposomes somewhat more leaky for protons in the absence of substrates. Is this just an artifact of the system, or does the presence of AcrA stimulate substrate-independent AcrD-mediated proton transport? Perhaps this system contains substrates even in the absence of aminoglycosides-possibly lipids or the valinomycin that was used to create the proton gradient?
More data are needed to understand whether the MFP is required for the transport activity of other reconstituted RND transporters. An MFP stimulated the activity of AcrB, though these data were interpreted in the context of membrane fusion (41) . Another reconstituted RND transporter, CzcA, had considerable transport activity in the absence of the corresponding MFP (13) .
How well can periplasmic capturing and subsequent transenvelope transport be described in terms of available concepts? Secondary transport in which the translocation of H ϩ is coupled to the transport of substrate against its concentration gradient comes in two forms: either "symport" or "antiport." In the former case, both proton(s) and substrate are transported in the same direction across the same membrane. In the latter case they cross the same membrane in opposite directions. Periplasmic capture followed by the release of a substrate into the external medium by a tripartite transporter complex does not fit either case: the H ϩ is moved across the inner membrane, while the substrate proceeds across the outer membrane of gram-negative bacteria. This type of transport mechanism calls for a new definition, and we will refer to it as "periport." Periport will qualify as a new mechanism of secondary transport only once it is shown to be fully reversible.
Reversible or not, periport as manifested by periplasmic substrate binding comes as very good news for those of us in the business of combating RND-efflux-mediated MDR with small-molecule inhibitors (21) . If substrates can be captured in the periplasm, the same can be true for inhibitors. Consequently, to inhibit an RND transporter, it may not be necessary to design a compound that can cross both membranes, which is a daunting challenge.
It is worth noting that periplasmic substrate capture and transenvelope export (periport) might be the basis of the high, nonadditive levels of antibiotic resistance that are observed when a single-component efflux pump, located in the inner membrane and extruding its substrates into the periplasm, and a tripartite RND-containing pump, picking substrates from there and exporting them into the external medium, are present in the same cell (19, 43) .
What is known about periplasmic binding sites? While the available structural data suggest that substrates bind in the central cavity between the transmembrane and periplasmic subunits (40) , the ligand-protein interactions in these complex structures appear weak and insufficient to explain substrate specificity. In fact, the few amino acid residue side chains observed to be interacting with the ligands are highly conserved across various efflux pump sequences of broadly varying substrate specificity. Analysis of the X-ray structure unveils a number of large lateral pockets within the periplasmic segment of AcrB (Fig. 1) . These lateral pockets stretch between the periplasm and the central cavity. Mutation data for several homologous RND transporters suggest the importance of a number of residues adjacent to these pockets for substrate transport and specificity (12, 22) . These observations are suggestive of an alternative pathway (dashed blue arrows) involving substrate binding in the peripheral pockets. The proximity of these pockets to the upper portal might allow their connection to the portal upon a conformational change associated with proton transport. It has previously been postulated (27, 28) that substrates that accumulate in the central cavity are actively transported into the upper portal space via the channel that should open along the central axis of the structure (solid blue arrows). However, a very significant conformational change associated with channel opening would have to be coupled with proton transport (turquoise arrow) via the transmembrane domain in order to accommodate the passage of substrates. The existence of additional binding pockets implies that in order to reach the headpiece funnel (and eventually the OMP tunnel) substrates do not need to use this central pore channel as a major substrate translocation pathway.
Although the substrate translocation pathway of RND transporters remains to be solved, the very fact of periplasmic capture differentiates them from the other families of MDR pumps, including ABC transporters such as the extensively studied human P-gp (4) and LmrA (38) from Lactococcus lactis; major facilitators such as LmrP (23), QacA (7), and MdfA (6) from L. lactis, Staphylococcus aureus, and E. coli, respectively; and SMR transporters such as EmrE (34) from E. coli. In all these cases the amino acid residues that are responsible for substrate specificity have been mapped to transmembrane domains, and in several instances membrane capture of substrates has been confirmed in rigorous biochemical experiments, justifying their characterization as "membrane vacuum cleaners" (16) . By the same token, capture of substrates by RND-type MDRs directly from the periplasm, coupled with extrusion across the outer membrane renders them periplasm vacuum cleaners (9) .
Another important aspect of the study of Aires and Nikaido was that AcrD was apparently able to capture its substrates from the cytoplasmic side as well. Not only that, but it also appeared to discriminate between different aminoglycosides: uptake from the cytoplasmic side was observed for gentamicin and tobramycin but not streptomycin. This result indicates a substrate-specific translocation pathway formed by the transmembrane domain. However, the finding that chimeric RND transporters containing periplasmic loops and transmembrane domains from different transporters (AcrB and AcrD [10] or MexY and MexB [8] ) retained the substrate specificity of the transporter from which the periplasmic loops were taken leaves us with the conclusion that substrate-specific binding sites are located in the periplasmic domains. More data are needed to resolve this contradiction. We note that both facilitated diffusion and active transport following cytoplasmic capturing has been demonstrated for the metal RND transporter CzcA in very similar reconstitution experiments. However, site-directed mutagenesis, targeting the most likely (but still somewhat limited) amino acid residues, did not succeed in identifying a cytoplasmic substrate-specific binding site (13) . The relevance of cytoplasmic capture per se in protection against compounds that attack bacteria from the outside is difficult to assess if the transporter is also able to extrude its substrates from the periplasm. Clearly it would be very useful for the cell if the transporter were able to catch even those molecules that had escaped periplasmic vacuuming. However, aminoglycosides appear to stimulate proton transport at concentrations (30 to 70 M) that are several orders of magnitude higher than those (20 to 30 nM) needed to inhibit protein synthesis (14) .
While one can argue about the importance of cytoplasmic capturing in protection against environmental toxins, it may be very important in providing defense against toxic charged metabolites, which might otherwise accumulate inside cells. In fact, induction of the expression of AcrB has been demonstrated in several mutants with blocks in biosynthetic pathways. These mutants accumulate biosynthetic intermediates formed before the block, leading to the suggestion that "toxic waste disposal" might be an important physiological function of AcrB (15) . Thus, the study by Aires and Nikaido has provided many important insights into the function of the MDR RND pump, a versatile and sophisticated transporter. Many unanswered questions remain. What is the mechanism of coupling of the proton translocation across the inner membrane with the transenvelope export of substrates? How many protons are translocated across the inner membrane per molecule of substrate exported? How is the activity of individual protomers coordinated? Are different substrates extruded with the same or varying rates? Can the polarity of transport by tripartite RND-containing transporters be reversed? It is clear that prevention of efflux-mediated MDR requires a detailed understanding of the molecular mechanism of transport as well as more high-resolution structures of transporter complexes.
